Srinivas Sridhar

About

Srinivas Sridhar, Ph.D. is University Distinguished Professor of Physics, Biomedical Engineering and Chemical Engineering at Northeastern University, and Lecturer on Radiation Oncology, Harvard Medical School. He previously served as Vice Provost for Research at Northeastern University, overseeing the University’s research portfolio.

An elected Fellow of the American Physical Society, Sridhar’s current areas of research are nanomedicine, neurotechnology and MRI imaging.  His paper in Nature in 2003 was listed among Breakthroughs of 2003 by the journal Science. He has published more than 200 articles on nanomedicine, neurotechnology, nanophotonics, metamaterials, quantum chaos, superconductivity and collective excitations in materials.

As Founding Director of the Nanomedicine Innovation Center at Northeastern University, Sridhar established a Nanomedicine Center for synthesis and characterization of nanoparticle formulations. His team has prepared and characterized several nanoplatforms ranging from lipid, polymeric and metallic nanoparticles to implants for sustained release for drug delivery of chemotherapeutics and biologics such as PARP inhibitors and siRNA, for application in cancer, cardiovascular and neurological diseases. With his students he has developed a groundbreaking approach to quantitative MRI that is soon to be tested in patients. An entrepreneur, he has founded companies that are translating his discoveries to the clinic.

Sridhar is passionately committed to training future scientists and engineers and providing access to knowledge to all particularly to those from under-represented minority communities. He has trained more than 120 faculty, postdoctoral fellows, scientists, and graduate and undergraduate students. He is Director of the Nanomedicine Academy funded by grants for NSF and NIH, whose vision is to providing training in nanomedicine nationally and globally.  He is Director of CaNCURE: Cancer Nanomedicine Coops for Undergraduate Research, an NIH R25 program to provide research training in cancer nanomedicine. He is Director and PI of the NSF IGERT Nanomedicine Science and Technology Center. He developed several first-of-their kind courses in Nanomedicine. These unique programs have taught hundreds of graduate and undergraduate students in several minority serving institutions, and led to institutional change in the form of new programs in nanomedicine. Sridhar’s contributions to education and training have been recognized by awards and invitations to speak and to participate in national panels on education.

For more information visit cancurecancer.org,  www.northeastern.edu/igert, srinivassridhar.com.

Selected Publications

• Zhang D., Singh B., Moerland J., Mitchell O., Lockwood L., Carapellucci S., Sridhar S., and Liby K.T. (2021). Sustained, Local Delivery of the PARP Inhibitor Talazoparib Prevents the Development of Mammary Gland Hyperplasia in Brca1-deficient Mice. Sci Rep, 11(1):1234. 10.1038/s41598-020-79663-7
• Yang S., Wallach M., Krishna A., Kurmasheva R., and Sridhar S. (2021). Recent Developments in Nanomedicine for Pediatric Cancer. J Clin Med, 10(7):1437. 10.3390/jcm10071437
• Rodell C.B., Baldwin P., Fernandez B., Weissleder R., Sridhar S., Dubach J.M. (2021). Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating in vitro and in vivo Encapsulated Drug Delivery. Adv Ther (Weinh), 4(3):2000125. 10.1002/adtp.202000125
• Versek C., Banijamali S.M.A., Bex P., Lashkari K., Kamarthi S., and Sridhar S. (2021). Portable Diagnostic System for Age-Related Macular Degeneration Screening Using Visual Evoked Potentials. Eye Brain. 13:111-127. 10.2147/EB.S295745
• Timms L., Zhou T., Lyu Y., Qiao J., Mishra V., Lahoud R.M., Jayaraman G.V., Allegretti A.S., Drew D., Seethamraju R.T., Harisinghani M., and Sridhar S. (2021). Ferumoxytol-enhanced Ultrashort TE MRA and Quantitative Morphometry of the Human Kidney Vasculature. Abdom Radiol (NY). 10.1007/s00261-021-02984-2. Online ahead of print.
• Singh B., Yang S., Krishna A., and Sridhar S. (2020). Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy. Front Chem.8:594619. 10.3389/fchem.2020.594619
• D. Zhang, P. Baldwin, A.S. Leal, S. Carapellucci, S. Sridhar, K.T. Liby, A Nano-Liposome Formulation of the Parp Inhibitor Talazoparib Enhances Treatment Efficacy and Modulates Immune Cell Populations in Mammary Tumors of BRCA- Deficient Mice, Theranostics, 9(21), 2019, 6224-6238
• J. Qiao, X. Cai, Q. Xiao, Z. Chen, P. Kulkarni, C. Ferris, S. Kamarthi, S. Sridhar, Data on MRI brain Lesion Segmentation using K-means and Gaussian Mixture Model-Expectation Maximization, Data Brief, 27, 2019, 104628
• P. Baldwin, A.W. Ohman, J.E. Medina, E.T. McCarthy, D.M. Dinulescu, S. Sridhar, Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model, Frontiers in Oncology, 9(353), 2019

Spotlight Story

Feb 23, 2024

Exploring a Wealth of Options to Pursue Unique Educational Paths

Julia Treese, E’24, chemical engineering, started her Northeastern journey in the Explore program. After three co-ops and a variety of extracurriculars, she has found that biotech is her calling.

Students

Apr 19, 2022

Congratulations RISE: 2022 Winners

Congratulations to our engineering students who won awards at the RISE:2022 Research, Innovation and Scholarship Expo!

Sep 29, 2015

Nanomedicine Academy for Minorities

COS Professor Srinivas Sridhar and ChE Professor & Chair Thomas Webster were awarded a $496K NSF grant to develop a "Nanomedicine Academy of Minority Serving Institutions".

Sep 18, 2015

Interdisciplinary Approach to Treat Vascular Diseases

ChE Assistant Professor Eno Ebong is using interdisciplinary research to search for the cause and treat­ment of vas­cular dis­eases that cause heart attacks and strokes.

Jun 23, 2015

CaNCURE – Cancer Nanomedicine Research Co-ops

As the first group of students finish their co-ops through the CaNCURE program, they describe their experiences as career-defining.

View All Related News